Wayne B. Harris
Expertise in
3
conditions

Dr. Wayne B. Harris

Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
38 Years of Experience
Expertise in
3
conditions
Emory Winship Cancer Institute
1365 Clifton Road Northeast, 
Atlanta, GA 

Overview

Wayne Harris is an Oncologist in Atlanta, Georgia. Dr. Harris has been practicing medicine for over 38 years is highly rated in 3 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Nephrectomy.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Loma Linda University School Of Medicine, 1988.0

Residency

Emory University School of Medicine

Specialties

Oncology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine, 1999

Fellowships

Emory University School of Medicine

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies
Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: July 19, 2022
Intervention Type: Other, Drug
Study Drug: Epsilon Aminocaproic Acid
Study Phase: Phase 2
View 13 Less Clinical Trials

35 Total Publications

Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Journal: Therapeutic advances in medical oncology
Published: August 28, 2024
Similar Doctors
Suresh S. Ramalingam
Expertise in
17
conditions
Dr. Suresh S. Ramalingam
Oncology
Expertise in
17
conditions
Dr. Suresh S. Ramalingam
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
34+ years
Languages Spoken:
English, Tamil
See accepted insurances
Offers Telehealth

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years is highly rated in 17 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
5
conditions
Dr. Carlton Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton Dampier
Hematology | Oncology

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (4.4 miles away)
404-785-9800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Mehmet A. Bilen
Expertise in
26
conditions
Dr. Mehmet A. Bilen
Oncology
Expertise in
26
conditions
Dr. Mehmet A. Bilen
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
18+ years
Languages Spoken:
English, Turkish
See accepted insurances
Offers Telehealth

Mehmet Bilen is an Oncologist in Atlanta, Georgia. Dr. Bilen has been practicing medicine for over 18 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy.

Frequently Asked Questions about Dr. Wayne B. Harris

How do I make an appointment with Dr. Wayne B. Harris?

You can book an appointment with Dr. Wayne B. Harris by calling their office at 404-778-1900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wayne B. Harris a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wayne B. Harris is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wayne B. Harris specialize in?

While Dr. Wayne B. Harris is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, and Nephrectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Wayne B. Harris participate in research or clinical trials?

Yes. Dr. Wayne B. Harris has published 35 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Wayne B. Harris's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Wayne B. Harris accept my insurance?

Dr. Wayne B. Harris accepts most major insurance plans, including Blue Cross Blue Shield and Oscar. We recommend calling the office directly at 404-778-1900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harris's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile